In January 2016 the Medical Technologies Evaluation Programme commenced the review of this guidance, to register as a stakeholder please contact us at firstname.lastname@example.org.
NICE has developed medical technology guidance on the VeriQ system for assessing graft flow during coronary artery bypass graft surgery.
NICE medical technologies guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
NICE has said the VeriQ system can be used to check for problems with coronary artery bypass grafts that could be corrected during surgery. Hospital teams may want to use the VeriQ system because it can reduce problems after coronary artery bypass graft surgery that are caused by graft failure, and may reduce the length of time people need to stay in hospital.
Next review: September 2020
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.